Business
Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd.
Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, has entered the Japanese market through a new customer relationship with Shionogi & Co., Ltd. (Shionogi), a major research-driven pharmaceutical company based in Japan.
About this update from Shionogi & Co., Ltd.
[{"type":"text","content":"BELFAST, Northern Ireland, Feb. 10, 2026 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, has entered the Japanese market through a new customer relationship with Shionogi & Co., Ltd. (Shionogi), a major research-driven pharmaceutical company based in Japan.","length":401,"tagName":"p"},{"type":"image","alt":"Cumulus_Logo","displaySize":"","headline":null,"caption":"Cumulus_Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":120,"url":"https://media.zenfs.com/en/cnwgroup.com/724ca139eb8be267f8e6b4b0e27c416b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HcN_rQ8Gvime_BHA8zbMjg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxMjtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/724ca139eb8be267f8e6b4b0e27c416b","width":400,"height":120}}},{"type":"text","content":"Shionogi will leverage the Cumulus NeuLogiq® Platform to generate objective neurophysiological data for S-898270, a novel therapeutic agent that selectively inhibits phosphodiesterase-4D (PDE4D) to enhance the early and late stages of memory formation. The study will be conducted in Japan, representing Cumulus' expansion into the Asian biopharma market. To support this and future studies, the NeuLogiq Platform has been translated into Japanese and Cumulus has expanded their team to support local clinical trial operations in Japan.","length":550,"tagName":"p"},{"type":"text","content":"Designed with 10 of the world's leading pharma companies, NeuLogiq® is an AI-based, multi-domain digital biomarker platform that provides biopharma partners and collaborators with a suite of state-of-the-art tools to help advance the discovery and development of new therapies for neuropsychiatric and neurodegenerative conditions.","length":340,"tagName":"p"},{"type":"text","content":""We have been working with the team at Shionogi since late 2024 and are impressed by their thoughtful approach to integrating NeuLogiq digital endpoints into the S-898270 Phase 1 study protocol," said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. "In July, our team presented data from CNS-101, our real-world observational study, at the Alzheimer's Association International C...